Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
30 drugs in development
By Therapeutic Area
top 6
R&D Momentum
89/100
Pipeline Velocity
63/100
Trial Completion Rate
76/100
Pipeline Concentration
16/100
Pipeline Freshness
63/100
Strategic Signals
Activity
Last 14 days
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
Cerebral Hemodynamics and Microemboli During Placement of Relay®Branch Thoracic Stent-Graft System
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
Neurobiological Correlates of Autobiographical Memory Training to Improve Opioid Use Disorder Outcomes
Social Virtual Reality to Alleviate Loneliness and Symptoms for Individuals Receiving Hemodialysis
Phase I Trial of TmCD19-IL18 CAR T Cells in Patients With Relapsed or Refractory CD19+ Cancers
Phase 1 Study of CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple Myeloma
Rapid Outpatient Low-dose Initiation of Buprenorphine for Individuals With OUD Using Fentanyl
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)